Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


01.04.2019

1 Actas Urol Esp
1 Arkh Patol
1 Biosci Rep
1 BJU Int
1 BMC Urol
1 Can Assoc Radiol J
1 Cancer Biomark
1 Cancer Causes Control
1 Cancer Med
1 Environ Toxicol Pharmacol
1 Eur Rev Med Pharmacol Sci
2 Eur Urol
5 Hinyokika Kiyo
1 Int J Clin Oncol
1 Int J Urol
1 J Cell Biochem
1 J Cell Mol Med
1 J Surg Oncol
6 J Urol
1 Mol Ther Methods Clin Dev
1 Mol Ther Nucleic Acids
1 Oncogene
1 PLoS One
1 Qual Life Res
2 Sci Rep
1 Sci Total Environ
4 Urol Int
3 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Actas Urol Esp

  1. SUBIRA-RIOS D, Herranz-Amo F, Renedo-Villar T, Moralejo-Garate M, et al
    Influence of laparoscopic access in cancer-specific mortality of patients with pTa-2pN0R0 bladder cancer treated with radical cistectomy.
    Actas Urol Esp. 2019 Mar 22. pii: S0210-4806(19)30004.
    PubMed     Text format     Abstract available


    Arkh Patol

  2. OSMANOV YI, Gaibov ZA, Kogan EA, Radenska-Lopovok SG, et al
    [Comparative morphological characteristics and immunophenotype of urothelial carcinomas of the renal pelvis and bladder].
    Arkh Patol. 2018;80:23-32.
    PubMed     Text format     Abstract available


    Biosci Rep

  3. ZHOU Q, Zhan H, Lin F, Liu Y, et al
    LincRNA-p21 suppresses glutamine catabolism and bladder cancer cell growth through inhibiting glutaminase (GLS) expression.
    Biosci Rep. 2019 Mar 22. pii: BSR20182372. doi: 10.1042/BSR20182372.
    PubMed     Text format     Abstract available


    BJU Int

  4. GROSS T, Furrer M, Schorno P, Wuethrich PY, et al
    Reproductive organ-sparing cystectomy significantly improves continence in women after orthotopic bladder substitution without affecting oncological outcome.
    BJU Int. 2018;122:227-235.
    PubMed     Text format     Abstract available


    BMC Urol

  5. CAO Q, Li P, Yang X, Qian J, et al
    Laparoscopic radical cystectomy with pelvic re-peritonealization: the technique and initial clinical outcomes.
    BMC Urol. 2018;18:113.
    PubMed     Text format     Abstract available


    Can Assoc Radiol J

  6. HASSANIEN OA, Abouelkheir RT, Abou El-Ghar MI, Badawy ME, et al
    Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Diagnostic Tool in the Assessment of Tumour Angiogenesis in Urinary Bladder Cancer.
    Can Assoc Radiol J. 2019 Mar 25. pii: S0846-5371(18)30206.
    PubMed     Text format     Abstract available


    Cancer Biomark

  7. CAO W, Zhao Y, Wang L, Huang X, et al
    Circ0001429 regulates progression of bladder cancer through binding miR-205-5p and promoting VEGFA expression.
    Cancer Biomark. 2019 Mar 12. pii: CBM182380. doi: 10.3233/CBM-182380.
    PubMed     Text format     Abstract available


    Cancer Causes Control

  8. ROSSI M, Strikoudi P, Spei ME, Parpinel M, et al
    Flavonoids and bladder cancer risk.
    Cancer Causes Control. 2019 Mar 22. pii: 10.1007/s10552-019-01158.
    PubMed     Text format     Abstract available


    Cancer Med

  9. SU H, Jiang H, Tao T, Kang X, et al
    Hope and challenge: Precision medicine in bladder cancer.
    Cancer Med. 2019 Mar 24. doi: 10.1002/cam4.1979.
    PubMed     Text format     Abstract available


    Environ Toxicol Pharmacol

  10. HERNANDEZ P, Alem D, Nieves M, Cerecetto H, et al
    Chemosensitizer effect of cisplatin-treated bladder cancer cells by phenazine-5,10-dioxides.
    Environ Toxicol Pharmacol. 2019;69:9-15.
    PubMed     Text format     Abstract available


    Eur Rev Med Pharmacol Sci

  11. ZHANG L, Yan R, Zhang SN, Zhang HZ, et al
    MicroRNA-338-3p inhibits the progression of bladder cancer through regulating ETS1 expression.
    Eur Rev Med Pharmacol Sci. 2019;23:1986-1995.
    PubMed     Text format     Abstract available


    Eur Urol

  12. UENO Y, Takeuchi M, Tamada T, Sofue K, et al
    Diagnostic Accuracy and Interobserver Agreement for the Vesical Imaging-Reporting and Data System for Muscle-invasive Bladder Cancer: A Multireader Validation Study.
    Eur Urol. 2019 Mar 25. pii: S0302-2838(19)30198.
    PubMed     Text format     Abstract available

  13. MOUW KW, Miyamoto DT, Efstathiou JA
    Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.01.040: Towards Biomarker-Informed M
    Eur Urol. 2019 Mar 22. pii: S0302-2838(19)30195.
    PubMed     Text format    


    Hinyokika Kiyo

  14. SHIMURA S, Matsumoto K, Tabata KI, Fujita T, et al
    [Recurrent Urothelial Carcinoma in the Uretero-Vesical Junction Treated with Partial Ureterectomy and Ureteroneocystostomy during Long-Term Follow-Up : A Case Report].
    Hinyokika Kiyo. 2018;64:157-160.
    PubMed     Text format     Abstract available

  15. OKUMURA A, Morii A, Takagawa K, Kitamura H, et al
    [A Case of Metastasis of Cholangiocarcinoma to the Bladder].
    Hinyokika Kiyo. 2018;64:165-168.
    PubMed     Text format     Abstract available

  16. KURAMOTO T, Nishikawa T, Nanpou Y
    [A Case Report of Granulomatous Renal Masses Following Intravesical Instillation of Bacillus Calmette-Guerin Therapy].
    Hinyokika Kiyo. 2018;64:225-230.
    PubMed     Text format     Abstract available

  17. MURAKAMI M, Kimura T, Iwamoto M, Honda M, et al
    [A Case of Metachronous Cancer Originating from Five Different Organs].
    Hinyokika Kiyo. 2018;64:231-234.
    PubMed     Text format     Abstract available

  18. OGAWA K, Shimizu Y, Tsuchihashi K, Kida K, et al
    [Two Cases of Inflammatory Myofibroblastic Tumor of the Urinary Bladder].
    Hinyokika Kiyo. 2018;64:445-450.
    PubMed     Text format     Abstract available


    Int J Clin Oncol

  19. GUO X, Liu M, Hou H, Liu S, et al
    Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.
    Int J Clin Oncol. 2019 Mar 22. pii: 10.1007/s10147-019-01427.
    PubMed     Text format     Abstract available


    Int J Urol

  20. NAKAYAMA M, Ito Y, Hatano K, Nakai Y, et al
    Impact of sex difference on survival of bladder cancer: A population-based registry data in Japan.
    Int J Urol. 2019 Mar 27. doi: 10.1111/iju.13955.
    PubMed     Text format     Abstract available


    J Cell Biochem

  21. LUO H, Xu C, Le W, Ge B, et al
    lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA-150.
    J Cell Biochem. 2019 Mar 27. doi: 10.1002/jcb.28622.
    PubMed     Text format     Abstract available


    J Cell Mol Med

  22. CHENG S, Qian K, Wang Y, Wang G, et al
    PPARgamma inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells.
    J Cell Mol Med. 2019 Mar 25. doi: 10.1111/jcmm.14280.
    PubMed     Text format     Abstract available


    J Surg Oncol

  23. WISSING MD, Santos F, Zakaria AS, O'Flaherty A, et al
    Short- and long-term survival has improved after radical cystectomy for bladder cancer in Quebec during the years 2000-2015.
    J Surg Oncol. 2019 Mar 28. doi: 10.1002/jso.25456.
    PubMed     Text format     Abstract available


    J Urol

  24. CHANG SS
    Re: Genomic Differences between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-Based Neoadjuvant Chemotherapy.
    J Urol. 2019 Mar 29:10109701JU0000557728168538.
    PubMed     Text format    

  25. XUE W, Yang L, Wei Q
    Re: Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: R. S. Liao, M. Gupta, Z. R. Schwen, H. D. Patel, M. Kates, M. H. Johnson, N. M. Hahn, D. McConkey, T. J.
    J Urol. 2018;200:1378-1379.
    PubMed     Text format    

  26. PARKER DC, Abboud MA, Patel SG
    Is Routine Removal of the Ovaries Advisable during Radical Cystectomy?
    J Urol. 2019;201:455-456.
    PubMed     Text format    

  27. CHANG SS
    Re: Mutational Patterns in Chemotherapy Resistant Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Mar 29:10109701JU000055772739723.
    PubMed     Text format    

  28. CHANG SS
    Re: Contemporary Treatment Patterns and Outcomes of Sarcomatoid Bladder Cancer.
    J Urol. 2019 Mar 29:101097JU0000000000000252. doi: 10.1097/JU.0000000000000252.
    PubMed     Text format    

  29. WHITSON JM
    Editorial Comment.
    J Urol. 2018;200:539-540.
    PubMed     Text format    


    Mol Ther Methods Clin Dev

  30. YOSHIKAWA Y, Taniguchi K, Tsujino T, Heishima K, et al
    Anti-cancer Effects of a Chemically Modified miR-143 on Bladder Cancer by Either Systemic or Intravesical Treatment.
    Mol Ther Methods Clin Dev. 2019;13:290-302.
    PubMed     Text format     Abstract available


    Mol Ther Nucleic Acids

  31. YU G, Zhou H, Yao W, Meng L, et al
    lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer.
    Mol Ther Nucleic Acids. 2019;16:257-271.
    PubMed     Text format     Abstract available


    Oncogene

  32. WU M, Sheng L, Cheng M, Zhang H, et al
    Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells.
    Oncogene. 2019 Mar 27. pii: 10.1038/s41388-019-0799.
    PubMed     Text format     Abstract available


    PLoS One

  33. YU A, Mansure JJ, Solanki S, Siemens DR, et al
    Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy.
    PLoS One. 2018;13:e0205746.
    PubMed     Text format     Abstract available


    Qual Life Res

  34. SHI H, Yu H, Bellmunt J, Leow JJ, et al
    Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis.
    Qual Life Res. 2018;27:2759-2775.
    PubMed     Text format     Abstract available


    Sci Rep

  35. LI A, Zhu X, Wang C, Yang S, et al
    Upregulation of NDRG1 predicts poor outcome and facilitates disease progression by influencing the EMT process in bladder cancer.
    Sci Rep. 2019;9:5166.
    PubMed     Text format     Abstract available

  36. BRIEU N, Gavriel CG, Nearchou IP, Harrison DJ, et al
    Automated tumour budding quantification by machine learning augments TNM staging in muscle-invasive bladder cancer prognosis.
    Sci Rep. 2019;9:5174.
    PubMed     Text format     Abstract available


    Sci Total Environ

  37. AMIN RW, Stafford B, Guttmann RP
    A spatial study of bladder cancer mortality and incidence in the contiguous US: 2000-2014.
    Sci Total Environ. 2019;670:806-813.
    PubMed     Text format     Abstract available


    Urol Int

  38. BO S, Donghao S, Guangqi K, Ye T, et al
    CC Chemokine Ligand 18 Promotes Cell Proliferation and Metastasis of Urothelial Carcinoma via Activating PI3K/mTOR Signaling in Patient with Renal Transplantation.
    Urol Int. 2018;101:450-458.
    PubMed     Text format     Abstract available

  39. LI A, Zhang P, Zhang M, Yang T, et al
    Transurethral Enucleation of Bladder Leiomyoma: A Series of Six Cases and Review of the Literature.
    Urol Int. 2019;102:102-108.
    PubMed     Text format     Abstract available

  40. TAE BS, Ku JH, Kwak C, Kim HH, et al
    Comparison of Renal Function after Radical Surgery for Upper Tract Urothelial Carcinoma versus Renal Cell Carcinoma: Propensity Score Matching.
    Urol Int. 2018;101:400-408.
    PubMed     Text format     Abstract available

  41. ZIESCHANG H, Koch R, Wirth MP, Froehner M, et al
    Leiomyosarcoma of the Urinary Bladder in Adult Patients: A Systematic Review of the Literature and Meta-Analysis.
    Urol Int. 2019;102:96-101.
    PubMed     Text format     Abstract available


    World J Urol

  42. VAN OSCH FHM, Nekeman D, Aaronson NK, Billingham LJ, et al
    Patients choose certainty over burden in bladder cancer surveillance.
    World J Urol. 2019 Mar 23. pii: 10.1007/s00345-019-02728.
    PubMed     Text format     Abstract available

  43. ZHANG G, Steinbach D, Grimm MO, Horstmann M, et al
    Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
    World J Urol. 2019 Mar 25. pii: 10.1007/s00345-019-02681.
    PubMed     Text format     Abstract available

  44. ZHANG L, Wu B, Zha Z, Zhao H, et al
    Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: a PRISMA-compliant systematic review and meta-analysis.
    World J Urol. 2019 Mar 27. pii: 10.1007/s00345-019-02738.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: